Exstent, a UK-based medical device company developing personalised external aortic support to preserve the natural aorta, today announced the appointment of Matt Thompson as Chief Executive Officer to lead its next phase of global growth.
Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles including President, CEO, and Chief Medical Officer at Endologix, guiding the company through transformation, portfolio growth, and the 2021 acquisition of PQ Bypass. Earlier in his career, Matt was Professor of Vascular Surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His experience in integrating novel endovascular technologies into established commercial frameworks aligns closely with Exstent’s strategic direction.
“Exstent’s personalised external aortic support is a meaningful advance in managing ascending aortic disease,” said Matt Thompson, CEO of Exstent. “It preserves native anatomy and offers a less invasive alternative to open graft replacement. My focus is to build on the company’s strong clinical foundation, expand access through collaboration, and position Exstent for sustainable growth.”
Exstent’s flagship innovation, Exovasc®, is a custom-made external support designed to reinforce the body’s major blood vessels and prevent dilation and dissection. Now used in more than 40 leading cardiac centres across the UK, Europe, Australia, and beyond, over 1,500 patients have been treated, with long-term data demonstrating excellent safety, valve preservation, and durability. Exstent is preparing for broader clinical adoption through strategic partnerships and scaled manufacturing.
Peter Philips, Chair of Exstent, added: “Exstent is entering a significant phase of expansion. Matt’s clinical expertise and commercial leadership will be instrumental as we move from strong foundations to broader adoption. We look forward to working with partners who share our commitment to improving outcomes in aortic disease.”
